Research Blends
GLOW
GLOW groups GHK-Cu, BPC-157 and a TB-500-listed component, bringing together separate lines of matrix-remodeling and tissue-signaling research.
$144USD / vial · 70 mg
Research only Research blend
CJC-1295 no DAC + Ipamorelin
Catalog size
$49
USD per vial · 10 mgCatalog price
Research onlyThis blend lists CJC-1295 without DAC and ipamorelin, linking two receptor pathways studied in pituitary growth-hormone secretion and short-term endocrine responses.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
No reservation or purchase is made by adding a material.
View documentation status ← Back to collection- Listed components
- CJC-1295 no DAC 5 mg + Ipamorelin 5 mg
- Format
- Awaiting confirmation
- Batch reports
- Check this size in the COA library
- Availability
- Confirmed during review
Catalog quantities are not assay results.
In the literature
The components. The research context.
GHRH-family and ghrelin-receptor research blend
Understanding the formulation
The listing pairs a no-DAC CJC material with ipamorelin in equal catalog quantities. “CJC-1295 without DAC” is commonly used for a modified GHRH fragment, but its exact sequence must be established by the specification. The published long-acting CJC-1295 program studied an albumin-reactive construct containing a drug affinity complex; that construct is not interchangeable with a no-DAC listing.
- Research class
- GHRH-family and ghrelin-receptor research blend
- Catalog search names
- CJC-1295 no DAC + Ipamorelin · CJC Ipa
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Why these components are studied
GHRH-family peptides signal through the pituitary GHRH receptor, while ipamorelin stimulates GH release through a different secretagogue pathway associated with the ghrelin receptor. A secretagogue is a molecule that prompts hormone secretion; these experiments measure the pituitary’s growth-hormone output. Distinct receptor pathways provide a reason to investigate interactions, but do not establish synergy, restoration of a normal secretion rhythm or clinical benefit from this exact blend.
Component and related research
These links provide research context; they do not confirm the exact materials in this formulation.
Documented lines of inquiry
Research areas
- 01
Construct and receptor identity
The foundational CJC-1295 work characterizes an albumin-binding GHRH analogue. It is useful for understanding the DAC distinction, but is related-compound evidence for this no-DAC formulation. [1]
- 02
Secretagogue pharmacology
Original ipamorelin experiments characterized endocrine responses and selectivity in animal systems. Claims about selectivity for GH release should remain tied to the species and measurements used. [2]
- 03
Human endocrine kinetics
A study in healthy male volunteers measured a transient episode of growth-hormone release after ipamorelin and modeled the relationship between peptide exposure and hormone response. It did not test this combination or measure lasting changes in sleep, body composition or performance. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Reading the evidenceWhat the studies
Component evidence · finished blend untested in cited studies
What the studies
can tell us.
Component evidence · finished blend untested in cited studiesDirect ipamorelin studies and related long-acting CJC-1295 studies address different molecules and study designs. No cited paper evaluates this finished no-DAC CJC/ipamorelin blend. Hormone measurements are intermediate physiological endpoints, rather than evidence for every proposed downstream benefit.
What remains uncertain
Do not transfer the prolonged activity of albumin-binding CJC-1295 to no-DAC material. Sequence, endocrine feedback, participant characteristics and analytical methods influence interpretation. A combined vial additionally requires its own identity, component-quantity and stability documentation; none is established by these literature references.
Read the source
Selected literature
These papers concern individual components or related molecules. They do not validate this finished blend.
- 01PubMed
Human growth hormone releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog (opens a new tab)
Defines the albumin-reactive CJC-1295 structure; related-compound evidence only for a no-DAC listing.
- 02PubMed
Ipamorelin, the first selective growth hormone secretagogue (opens a new tab)
Original pentapeptide pharmacology; ACTH/cortisol selectivity findings were established in animal experiments.
- 03PubMed
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers (opens a new tab)
Healthy-volunteer endocrine kinetics; not a long-term efficacy study.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Before you begin
The details behind
the material.
Specifications and storage
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
Research use only
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAContinue exploring.
All materialsOther research blends in the collection.
View details
Research Blends
KLOW
KLOW lists GHK-Cu, BPC-157, TB-500 and KPV, connecting component studies of skin-matrix remodeling, cell migration and intestinal inflammatory signaling.
$129USD / vial · 80 mg
Research only
Research Blends
Wolverine
Wolverine pairs BPC-157 with a TB-500-listed component, connecting preclinical tendon and gastrointestinal research with thymosin-related identity questions. The exact TB-500 sequence still requires confirmation.
$65USD / vial · 10 mg
Research only